Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine and cisplatin versus placebo plus gemcitabine and cisplatin in first-line advanced biliary tract cancer
CTR20191450Phase 3Completed
- Sponsor
- MedImmune
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer, sponsored by MedImmune. Started Sep 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20191450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191450.